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Abstract
This prospective study evaluates haemodynamic and electroencephalographic effects observed when administering four 
combinations of effect-site concentrations of propofol  (CePROP) and remifentanil  (CeREMI), all yielding a single predicted 
probability of tolerance of laryngoscopy of 90%  (PTOL = 90%) according to the Bouillon interaction model. We aimed to iden-
tify combinations of  CePROP and  CeREMI along a single isobole of  PTOL that result in favourable hypnotic and haemodynamic 
conditions. This knowledge could be of advantage in the development of drug advisory monitoring technology. 80 patients 
(18–90 years of age, ASA I–III) were randomized into four groups and titrated towards  CePROP (Schnider model, ug⋅ml−1) 
and  CeREMI (Minto model, ng⋅ml−1) of respectively 8.6 and 1, 5.9 and 2, 3.6 and 4 and 2.0 and 8. After eleven minutes of 
equilibration, baseline measurements of haemodynamic endpoints and bispectral index were compared with three minutes of 
responsiveness measurements after laryngoscopy. Before laryngoscopy, bispectral index differed significantly (p < 0.0001) 
between groups in concordance with  CePROP. Heart rate decreased with increasing  CeREMI (p = 0.001). The haemodynamic 
and arousal responses evoked by laryngoscopy were not significantly different between groups, but  CePROP = 3.6 μg⋅ml−1 
and  CeREMI = 4 ng⋅ml−1 evoked the lowest median value for ∆HR and ∆SAP after laryngoscopy. This study provides clini-
cal insight on the haemodynamic and hypnotic consequences, when a model based predicted  PTOL is used as a target for 
combined effect-site controlled target- controlled infusion of propofol and remifentanil. Heart rate and bispectral index were 
significantly different between groups despite a theoretical equipotency for  PTOL, suggesting that each component of the 
anaesthetic state (immobility, analgesia, and hypnotic drug effect) should be considered as independent neurophysiological 
and pharmacological phenomena. However, claims of (in)accuracy of the predicted  PTOL must be considered preliminary 
because larger numbers of observations are required for that goal.
Keywords Pharmacology · Interaction · Haemodynamic monitoring · Electroencephalographic monitoring
1 Introduction
Pharmacodynamic drug interactions are classically 
described using isoboles, which are iso-effect lines that 
connect all combinations of drug concentrations resulting 
in an equivalent clinical drug effect [1]. Combining sev-
eral isoboles in a three dimensional response surface model 
allows depiction of the total spectrum of the interaction 
between two drugs in relation to a specific effect of interest 
(Fig. 1). For example, the probability of tolerance to laryn-
goscopy  (PTOL) can be predicted using response surface drug 
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interaction models, for any combination of effect-site con-
centrations of propofol  (CePROP) and remifentanil  (CeREMI) 
[2, 3], and it has been incorporated into commercially-avail-
able anaesthesia monitors, called advisory displays [1, 4]. 
The bedside availability of  PTOL creates opportunities for the 
clinician to improve the control over one of the main compo-
nents of anaesthetic drug effect: the immobility in response 
to a noxious stimulus [1, 5, 6]. It now is clinically feasible 
to titrate different combinations of  CePROP and  CeREMI while 
maintaining a constant effect estimated by  PTOL. However, 
there is limited information whether titration towards vari-
ous combinations of  CePROP and  CeREMI, that yield a similar 
 PTOL, will be equally beneficial for the patient in view of 
electroencephalographic and haemodynamic effects, respec-
tively representing the hypnotic and analgetic component of 
anaesthesia [2, 3, 6–11].
For electroencephalographically-derived indices monitor-
ing hypnotic drug effect, such as the bispectral index (BIS)
(Medtronic, Minneapolis, Minnesota, USA), Bouillon and 
coworkers predict that BIS will decrease in concordance 
with increases in  CePROP, however this observation merits 
prospective confirmation [2]. In contrast, for commonly 
monitored haemodynamic endpoints, such as heart rate 
(HR), systolic arterial blood pressure (SAP), stroke vol-
ume (SV), cardiac index (CI), systemic vascular resistance 
(SVR), and the systemic vascular resistance index (SVRI), 
it is striking that the interaction between  CePROP and  CeREMI 
has not been described equally thorough using isoboles or 
response surface interaction models.
Therefore, this study explores the clinical consequences 
of a  PTOL guided titration using effect-site controlled infu-
sion of propofol and remifentanil, in order to provide helpful 
insight on the haemodynamic and hypnotic consequences 
of this titration concept, using clinical advisory display 
monitors. The primary purpose was to compare the haemo-
dynamic and electroencephalographic effects observed 
between four different combinations of  CePROP and  CeREMI, 
all yielding a  PTOL of 90% as estimated by Bouillon et al. [3], 
both during steady-state conditions (before laryngoscopy), 
as well as in response to a laryngoscopy. For all measured 
endpoints, we hypothesize that no significant difference 
would be found between groups because the clinical condi-
tion is estimated to be equipotent for  PTOL.
As commercially advisory monitors become available 
as a monitoring tool to guide titration of combinations of 
drugs towards equipotency for PTOL [1], this study is a 
first attempt to explore the subsequent haemodynamic con-
sequences of such actions in a prospective study. It must be 
demonstrated in a standardised and reproducible way that it 
is clinically safe to adjust drug administration according to 
the advice provided by these new advisory monitors.
2  Materials and methods
Following Ethics Committee approval (University Medi-
cal Center Groningen, University of Groningen, Gronin-
gen, The Netherlands, METc 2013/267) and clinical trial 
Fig. 1  The left panel shows the three-dimensional response surface 
model of propofol and remifentanil based on the data of Bouillon 
et  al. [3].  A response surface model is a mathematical description, 
visualized in a 3-dimensional graph depicting the effect (in this case, 
the probability of tolerance of laryngoscopy  (PTOL)) (z-axis) evoked 
by combining two different drugs (respectively the effect-site concen-
tration of propofol and remifentanil in the x and y axis). The thick 
line represents the  PTOL = 90% isobole, which is also depicted in the 
two-dimensional cross-sectional graph (right panel), representing the 
isoboles that connect all combinations of drugs that evoke identical 
effect. The bullets on the isobole represent the four drug combina-
tions used in this study (A-D from left to right, respectively)
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registration (ClinicalTrials.gov, #NCT02067936, principal 
investigator: H.E.M. Vereecke, Date of Registration: Feb-
ruary 20th 2014, https ://goo.gl/z23qJ G) prior to patient 
enrolment, written informed consent was obtained from 80 
patients (18–90 years of age, ASA I–III) scheduled for gen-
eral anaesthesia for elective neurosurgical or maxillofacial 
surgical procedures. Exclusion criteria were BMI exceeding 
35 kg∙m−2, allergies for either propofol and/or remifentanil, 
overt signs of alcohol or drug abuse, diseases of the central 
nervous system, hepatic disease (i.e. Child B or higher), the 
use of drugs acting on the central nervous system, and the 
use of α-or β-receptor agonists or antagonists. Patients sus-
pected for having a difficult airway were excluded to ensure 
a safe mask ventilation throughout the measurements.
2.1  Study design
The study was designed as a prospective double-blind, ran-
domized, interventional trial. All measurements and study 
interventions were performed in a quiet operating room, 
before surgery commenced. After screening for eligibility 
and informed consent, 80 patients were randomized into four 
groups of 20 participants each, using sealed envelopes drawn 
at random. Patients received 1000 mg paracetamol as pre-
medication. No benzodiazepine or other sedative drug was 
administered to the patient prior to the procedure.
The anaesthesiologist who performed mask ventilation, 
laryngoscopy, and the observation of motor response was 
blinded to group allocation. If any airway problem occurred 
at any time during the study, the anaesthesiologist could 
decide to un-blind the randomization and take all necessary 
measures. Such patients were excluded from further data 
analysis and replaced. Administration of the drugs and data 
collection was performed by an (unblinded) researcher who 
operated a laptop running RUGLOOP II software (Demed 
Engineering, Temse, Belgium), a data collection program 
which also controls the target-controlled infusion pumps.
An intravenous line was inserted in a large forearm 
vein. Electrocardiography (ECG), pulse-oximetry  (SpO2), 
and intermittent non-invasive blood pressure (NIBP) was 
measured using the Philips Intellivue MP70 patient monitor 
(Philips Healthcare, Eindhoven, The Netherlands). CI, SV, 
SVI and SVRI were measured continuously by the ccNexfin 
Monitor (BMEYE, Amsterdam, Netherlands; now Edwards 
Lifesciences, Irvine, CA, USA). Measurements were per-
formed using a non-invasive ccNexfin finger cuff attached 
to the third digit of the contralateral hand of the NIBP meas-
urements. The heart reference system (HRS™) of Nexfin® 
was positioned at mid-axillary level in the supine positioned 
patient to calibrate for hydrostatic pressure differences 
between the position of the finger and the level of the heart.
Bispectral index was measured using a unilateral BIS Qua-
tro Sensor (and a BIS Vista monitor (all: Medtronic, Dublin, 
Ireland), smoothing delay time was set at 15 s with data stor-
age every second. BIS and suppression ratio were compared 
between groups.
2.2  Study drug administration
Propofol 2% (Braun, Melsungen, Germany) and remifentanil 
50 µg⋅ml−1 (GlaxoSmithKline BV, Zeist, The Netherlands) 
were both administered by means of RUGLOOP II, a data 
collection and drug delivery software that runs on a PC (Penta 
Hercules Medical ETX, Penta GmbH, Mönchengladbach, 
Germany) connected to infusion pumps (Asena GH, Bec-
ton Dickinson, San Diego, California, USA) and monitoring 
devices through USB ports, RS-232 interface and LAN con-
nectivity. The software collects all data in a time-synchronized 
way. The pumps administer propofol and remifentanil using 
an effect-site controlled target-controlled infusion with maxi-
mum infusion rates of 600 and 1200 ml⋅h−1 respectively. For 
calculating  CePROP and  CeREMI the pharmacokinetic-dynamic 
models of Schnider and Minto respectively were applied [7, 8]. 
For the Schnider model, the elimination equilibration constant 
of the effect-site (ke0) was fixed to 0.456 min−1. These models 
are identical to those used by Bouillon and coworkers for the 
interaction model development [3].
2.3  Study procedure
After checking signal quality of all measurements, and before 
any drug was administered, patients were asked to close their 
eyes for 2 min for registration of awake measurements while 
breathing 100% oxygen through a gently applied face mask. 
Next, propofol and remifentanil infusions were started simul-
taneously, targeted to one out of four equipotent drug combina-
tions of  CeREMI and  CePROP (see Fig. 1). These combinations 
were determined as follows: First, four values of  CeREMI were 
chosen over a wide clinically relevant range, i.e. 1, 2, 4 and 
8 ng⋅ml−1 for groups A, B, C and D, respectively. The corre-
sponding  CePROP resulting in  PTOL = 90% was obtained from 
the sigmoidal response function for a dichotomous effect [2, 
9, 10].
where γ is the slope parameter, representing the steepness of 
the concentration-effect relationship, and U is the combined 
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where  Ce50PROP is the effect-site concentration of propofol 
resulting in  PTOL = 0.5 if given alone, and  Ce50REMI is the 
 CeREMI that results in an increase of U by a factor 2 or an 
apparent decrease of  Ce50PROP by 50%. The model param-
eters of the Bouillon study were taken from Table 1 of the 
article by Hannivoort et al. [10]:  Ce50PROP = 8.48 µg⋅ml−1, 
 Ce50REMI = 1.16 ng⋅ml−1 and γ = 3.46. It follows from Eq. 1 
that U = 1.887 for  PTOL = 90%. For each of the four remifen-
tanil concentrations, the corresponding propofol concentra-
tion was calculated from Eq. 2, resulting in the previously 
mentioned drug dose combinations.
Once  CePROP and  CeREMI reached the desired target, 
eleven minutes of equilibration time ensures minimal pre-
diction errors of the applied models during the observations 
[11]. Subsequently, one minute of baseline measurement was 
performed followed by a laryngoscopy, with an aim to visu-
alize the larynx and thereby exert a standardized noxious 
stimulus, for a duration of 10 s. The time point of ‘laryngo-
scopy’ originally was registered as the moment of full trac-
tion on the laryngoscope. We noticed during the conduct of 
the study that the manipulations to start laryngoscopy (such 
as removal of the face mask and oral introduction of the 
laryngoscope) may already have triggered haemodynamic, 
motor, or electroencephalographic responses in some cases, 
several seconds before maximum traction was reached. For 
the analysis of data, we pragmatically defined the “start 
of laryngoscopy” as a time point 30 s before full traction 
was applied. After laryngoscopy, another three minutes of 
data registration were maintained to observe the presence 
or absence of movement and haemodynamic or electroen-
cephalographic measurements. Motor response was defined 
as movement of extremities, opening of eyes, gag reflex or 
coughing within three minutes after the initial manipula-
tions for starting laryngoscopy. After the three minutes 
observation of response, the study ended, and regular care 
was resumed.
2.4  Safety precautions
In case of unsustainable respiratory inhibition or apnea 
during induction or during the equilibration time, gen-
tle airway manoeuvres (e.g. adjustment of the face mask, 
chin lift, hyperextension or pillow adjustments) were per-
formed to facilitate mask-bag ventilation. In case of diffi-
culties to obtain an open airway, or haemoglobin oxygen 
desaturation, an oropharyngeal airway was introduced. If 
respiratory escape manoeuvres caused a motor, haemody-
namic, or arousal response during the measurements of 
Table 1  Patient characteristics and comparison between haemodynamic- and electroencephalographic baseline measurements. Baseline heart 
rate was different between groups (p < 0.000), as was BIS between groups (p < 0.001)
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the pre-stimulation baseline minute (minute 10 to 11) the 
patient was excluded from analysis, due to the lack of steady 
state conditions. In case of bradycardia below 40·min−1 
or a decrease in mean arterial pressure below 50 mmHg, 
respectively 0.5 mg of atropine or 5 mg of ephedrine, was 
administered as rescue medication. The number of rescue 
interventions and the total dose of atropine and ephedrine 
were also registered for comparison between groups.
2.5  Statistics and data analysis
For the primary haemodynamic and electroencephalographic 
endpoints, no previous data was available to make reason-
able assumptions for an a-priori power calculation of the 
sample size required. We thus pragmatically chose to include 
20 patients per group, based on our previous experiences in 
pharmacodynamic studies. In this clinical evaluation study, 
we accepted the validity and accuracy of the published val-
ues for  PTOL[3].
All collected data from different storage systems was 
synchronized using an algorithm in R (R, The R founda-
tion for statistical computing, Vienna, Austria), after reject-
ing obvious false values (e.g. negative blood pressure). The 
algorithm defined a short-lasting (< 1 sec) difference of 
30% between two subsequent time points (1 s interval) as an 
artefact. BIS-measurements with a signal quality index < 50 
were removed. All raw data (after artefact rejection) of the 
haemodynamic and BIS-measurements were plotted from 
the baseline minute to three minutes after laryngoscopy. We 
also plotted SR as measured by BIS.
Significant difference was defined when p < 0.05. Base-
line characteristics were compared using ANOVA tests or a 
non-parametric Kruskal Wallis test with Nemenyi post hoc 
test, depending on normality of the distribution, which was 
tested using the Shapiro–Wilk test. After testing for normal-
ity, haemodynamic variables, (HR, SAP, CI, SVI, SVRI) and 
BIS were compared between groups, both at baseline and 
in response to laryngoscopy. The median and range of the 
baseline data were compared using a Kruskall-Wallis test.
To allow a comparison of the magnitude of haemody-
namic (∆HR, ∆SAP, ∆CI, ∆SVI, ∆SVRI) and arousal 
responses (∆BIS) evoked by laryngoscopy between groups, 
the difference between the median of the baseline values and 
the maximum value observed during the response period 
was calculated for all endpoints and for each subject, and 
then averaged (median ± standard deviation) for the popula-
tion. A Kruskall-Wallis test was used to test for significant 
differences between groups.
Whenever the individual ∆HR, ∆SAP, ∆CI, ∆SVI, 
∆SVRI exceeded 20% of the baseline value, we defined 
that case as a “haemodynamic responder” and compared 
the number of responders between groups. A threshold 
of 20% was chosen as it is a commonly used definition of 
perioperative hypotension in current literature [12–14]. For 
∆BIS, we also counted the number of arousal responses in a 
similar fashion, but used a 30% threshold instead. Changes 
in BIS < 20% rarely trigger a therapeutic intervention 
because fluctuations of that magnitude over time are com-
mon for BIS [15].
3  Results
An overview of the screenings/inclusion/exclusions can be 
found in the CONSORT diagram (Fig. 2). Patient charac-
teristics are described in Table 1. No serious adverse events 
occurred during the conduct of the study. 87 patients were 
randomized to the four groups. In groups C and D, 3 and 
4 patients were replaced, respectively. The remaining 80 
patients were included in the data analysis. The patient 
characteristics were comparable between groups (Table 1, 
panel A).
In Figs. 3 and 4, the haemodynamic and electroencepha-
lographic endpoints, respectively, are plotted over time 
from the baseline measurements till the end of the response 
observation time. These figures give an impression of the 
population variability at baseline for each studied meas-
urement, and the magnitude of the respective responses to 
laryngoscopy.
We observed 2, 1, 4, and 8 motor responders after laryn-
goscopy in group A, B, C, and D, respectively. The higher 
number of responders in group D may be related to several 
patients who did not reach a sufficient level of hypnotic drug 
effect before laryngoscopy, as also reflected in the high BIS 
values. Even the removal of the face mask resulted in return 
of responsiveness for some patients of group D.
Table 1 panel B shows the statistical results for the com-
parison of the baseline measurements between groups. HR 
at baseline was significantly higher in groups A and B versus 
C and D (p < 0.000): median HR (25–75% range) for groups 
A, B, C and D were 71 (59–73), 68 (63–72), 60 (56–63) 
and 60 (56–62) beats⋅min−1, respectively. Median CI was 
0.3 L⋅min−1 higher in groups A and B compared to C and 
D (not statistically significant, p = 0.162). Median SAP, CI, 
SVI and SVRI were not significantly different at baseline 
between groups.
Table 2 shows the results of the magnitude of the haemo-
dynamic and arousal responses after laryngoscopy (∆HR, 
∆SAP, ∆CI, ∆SVI, ∆SVRI, ∆BIS). The median haemody-
namic responses evoked by laryngoscopy were moderate and 
not significantly different between groups for all measured 
variables. Group C had the lowest median value for ∆HR 
and ∆SAP.
We identified 5 (25%), 6 (30%), 7 (35%), and 9 (45%) HR 
responders in groups A, B, C, and D, respectively, who had 
a 20% increase of HR evoked by laryngoscopy.
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For ∆SAP, groups A and B contained almost double the 
number of responders of groups C and D (16, 17, 8, and 9 
for groups A, B, C, and D, respectively).
After induction and during the equilibration phase, 
respectively 7, 4, 10, and 5 out of 20 patients in group A, B, 
C, and D needed rescue medication for hypotension being 
one or two administrations of ephedrine 5 mg, before base-
line measurements were performed. No administration of 
ephedrine was needed during the steady state measurements. 
No atropine was administered as a rescue for bradycardia.
For BIS at baseline, groups A and B showed signifi-
cantly lower BIS (p < 0.000) at baseline compared to groups 
C and D (Table 1, Panel B), which is consistent with the 
higher  CePROP in groups A and B. Also, groups A and B 
contained the highest number of cases with SR levels > 5% 
(Fig. 4). In group C, we observed the highest number of 
patients with continuous BIS values that remained within 
the desired range (between 40 and 60). (Fig. 4). Only 3 out 
of 20 patients showed minimal burst suppression patterns 
(SR < 5%) at baseline in group C.
For the BIS response to laryngoscopy, only group A 
showed a statistically significant lower ΔBIS compared 
to group C (p = 0.011), which may be related to the high 
incidence of SR > 5% at baseline, indicating excessive 
hypnotic drug effect in group A. For all other groups ΔBIS 
was indistinguishable between groups. The number of BIS 
Fig. 2  CONSORT diagram
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arousal responses (> 30% increase after laryngoscopy) 
was respectively 25, 40, 40, and 10% for groups A to D. 
The low incidence of arousal in group A and D are prob-
ably both biased due to respectively the high incidence of 
SR > 5% in group A and the high baseline BIS values in 
group D that cannot rise another 30%.
4  Discussion
This study explores the haemodynamic and hypnotic 
effects evoked by four different combinations of  CePROP 
and  CeREMI, all yielding an identical predicted  PTOL 
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Fig. 3  The evolution of the observed haemodynamic variables 
between − 60 to + 120  s from the start of laryngoscopy (Time = 0). 
The grey lines represent the results for each individual patient. The 
black line is the population median value. Group A (remifentanil 1 ng 
⋅  ml−1 and propofol 8.6 µg ⋅  ml−1), Group B (remifentanil 2 ng ⋅  ml−1 
and propofol 5.9 µg ⋅  ml−1), Group C (remifentanil 4 ng ⋅  ml−1 and 
propofol 3.6 µg ⋅  ml−1), and Group D (remifentanil 8 ng ⋅  ml−1 and 
propofol 2.0 µg ⋅  ml−1)
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according to the Bouillon interaction model.  PTOL is a 
theoretical -population derived- metric for immobility in 
response to a noxious stimulus and has been integrated 
in clinically-available advisory monitors for drug titra-
tion during anaesthesia, however, the clinical usefulness 
still needs further prospective validation. In this clinical 
evaluation study, we accepted the validity and accuracy 
of the published values for  PTOL[3]. As such, any claim 
of (in)accuracy of the predicted  PTOL must be considered 
preliminary because larger numbers of observations are 
required for that goal. However, as commercialized advi-
sory screens are already clinically available to allow titra-
tion towards this population derived prediction of  PTOL, 
our current dataset does provide valuable information on 
































































































































−60 0 60 120 180
Time (sec) Time (sec)
Fig. 4  The evolution of the observed electroencephalographic 
variables between − 60 to + 120  s from the start of laryngoscopy 
(Time = 0). The grey lines represent the results for each individ-
ual patient. The black line is the population median value. Group 
A (remifentanil 1  ng ⋅  ml−1 and propofol 8.6  µg ⋅  ml−1), Group 
B (remifentanil 2  ng ⋅  ml−1 and propofol 5.9  µg ⋅  ml−1), Group C 
(remifentanil 4 ng ⋅  ml−1 and propofol 3.6 µg ⋅  ml−1), and Group D 
(remifentanil 8 ng ⋅  ml−1 and propofol 2.0 µg ⋅  ml−1). BIS SR = sup-
pression ratio as measured by the bispectral index monitor
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the haemodynamic and hypnotic consequences of such 
deliberately combined drug titration using effect-site con-
trolled target-controlled infusion [5, 16].
We did find that titration towards the four theoretically 
equipotent combinations of  CePROP and  CeREMI (for pre-
dicted  PTOL = 90%) does result in moderate -but clinically 
relevant- differences of haemodynamic and hypnotic drug 
effects between groups.
Before laryngoscopy, similar SAP, CI, SVI, and SVRI 
was found in all groups except for heart rate, which was 
moderately (but statistically significant) lower in groups with 
higher  CeREMI concentrations. This is in concordance with a 
study of Hayashi and coworkers showing a cut-off point for 
heart rate reduction at remifentanil concentrations around 
3.5 ng⋅ml−1[17].
The apparent similar haemodynamic state between 
groups before laryngoscopy could only be achieved after 
a variable number of patients reached a safety threshold 
during the non-steady state induction of anaesthesia. They 
needed rescue treatment with ephedrine at variable time-
points. We were not able to identify any causal relationship 
between the occurrence of such events and group randomi-
zation, neither for the number of rescue treatments nor for 
the total dose of ephedrine administered. This observa-
tion may challenge the commonly accepted notion that 
high levels of opioids during balanced anaesthesia result 
in more stable haemodynamic conditions. It merits fur-
ther research towards the immediate haemodynamic effects 
evoked by the non-steady state induction of anaesthesia, 
using effect-site controlled target-controlled infusion. For 
this study pharmacological steady-state conditions were 
required, which was only reached after an equilibration 
period of 11 min. As such, we cannot report on observa-
tions during non-steady state conditions.
After laryngoscopy, one would expect the lowest haemo-
dynamic response in groups with higher  CeREMI, however, 
the median haemodynamic responses (∆HR, ∆SAP, ∆CI, 
∆SVI, ∆SVRI) were moderate in severity and not signifi-
cantly different between groups (Table 2). The number of 
patients that showed a > 20% difference in baseline HR was 
similar for groups A, B, and C. Group D had the highest inci-
dence (45%) of HR responses. This finding may be a biased 
by the substantial number of patients with high BIS (> 60) 
in group D, suggesting an insufficient hypnotic drug effect. 
Indeed, several patients immediately opened their eyes once 
the face mask was removed and before laryngoscopy could 
be initiated. For ∆SAP, groups A and B contained almost 
double the number of responders of groups C and D, which 
is concordant with the higher  CeREMI in groups C and D.
BIS showed significant differences in baseline measure-
ments with several cases of high SR > 5%, indicating an 
excessive hypnotic drug effect in groups A and B (Fig. 4). 
In contrast, group D included many cases of BIS above the 
upper limit threshold of 60 (increasing the risk for conscious 
perception). Therefore, BIS appears to be inversely related 
to  CePROP, which agrees with earlier studies [10, 18]. An 
arousal response of BIS evoked by laryngoscopy may be a 
sign of inadequate analgesic effect and is associated with 
increased risks for unintentional conscious perception [19]. 
The magnitude of arousal, measured by BIS, was small in 
our study and not significantly different between groups 
(Table 2).
Our data allows to identify whether some combi-
nations of  CePROP and  CeREMI evoke more favourable 
Table 2  Comparison of difference between the median value before versus the maximum value after laryngoscopy for each variable. BIS was 
different between groups (p = 0.006), as was systolic blood pressure (p = 0.03)
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haemodynamic  conditions, when evaluating all effects 
together. We found that in group C, during baseline meas-
urements, only a moderate decrease in HR and no significant 
difference in SAP was observed compared to other groups. 
Group C also contained the highest number of patients 
with an adequate BIS range before laryngoscopy while the 
absence of high SR suggests absence of overdosing of hyp-
notic drug effect. Group C also had the lowest median value 
for ∆HR and ∆SAP evoked by laryngoscopy. We observed 4 
motoric responders out of 20 in group C, which is an accept-
able clinical result, considering the predicted  PTOL = 90% 
and its corresponding confidence interval (not published 
post-hoc analysis). However, the latter conclusion must be 
interpreted cautiously due to the insufficient power of our 
study to validate the accuracy of  PTOL as a metric of drug 
effect.
In conclusion, this study provides clinical insight on the 
haemodynamic and hypnotic consequences, when a model 
based predicted  PTOL is used as a target for combined intra-
venous administration of propofol and remifentanil, using 
effect-site controlled target-controlled infusion pumps. Heart 
rate and bispectral index were significantly different between 
groups despite a theoretical equipotency for  PTOL, suggesting 
that each component of the anaesthetic state (immobility, 
analgesia, and hypnotic drug effect) should be considered 
as independent neurophysiological and pharmacological 
phenomena.
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